Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that has been regarded as a valuable molecular target following the success of a cMet and ALK inhibitor, crizotinib, in non-small cell lung cancer (NSCLC) tumors with ALK gene rearrangement [9,10]. The gene discussed is NTRK1; the disease is non-small cell lung carcinoma.